Aesthetics Biomedical® Inc. Announces Issuance of its Third U.S. Patent for "Biological Preserving Composition and Methods of Use" for its SoME® Skincare Product Line

The biological patent confirmed covers topical compositions for combining biologics with skincare preserving the exclusivity of SoME® Skincare.

PHOENIX,  August 10, 2022 /PRNewswire-PRWeb/ -- Aesthetics Biomedical® Inc (ABM), a leader in regenerative medicine and advanced aesthetics committed to the development and distribution of breakthrough, novel, and personalized aesthetic devices and products announces the issuance of its third US patent for "Biological Preserving Composition and Methods of Use" from the United States Patent Trademark Office. The newly issued [third] patent continues the protection of its innovation in the proprietary topical compositions of its SoME® Skincare product which combines with physician infused biologics and presents the future of personalized skincare.

Founder & Chief Executive Officer, MaryAnn Guerra says of the issuance "Once again, I am excited to see that Aesthetics Biomedical's innovations have been validated by the issuance of a new patent, further strengthening our SoME® Skincare brand and patent portfolio. Our SoME® Skincare product line will be expanded to fully utilize the broader patent coverage, under the leadership of our Director of Innovation & Design, Shaun Wootten."

SoME® Skincare, medically dispensed through professional offices, with its unique technology platform combines the body's own regenerative cytokines within skincare. Proven in skin renewal and regeneration, SoME® Skincare is clinically shown to improve both visual and cellular facial aging. "This latest, additional patent for preserving biologics marks a paradigm shift for skincare and adds additional protection to Aesthetics Biomedical's product portfolio", said Shaun Wootten, Director of Innovation and Design. "This is Aesthetics Biomedical's broadest patent yet on the matter and cements the ingenuity of our Center of Aesthetic Innovation."

The growth factors, derived from Platelet Rich Plasma [PRP] infused within its advanced formula signals the biochemical receptors on the cell surface to stimulate new collagen and new elastin critical for regeneration and repair of photodamaged skin to produce a personalized, autologous skincare treatment. Aesthetics Biomedical® Inc. is continuing to build its pipeline of regenerative products with a focus on skin, hair, and nail personalized products. The patents cover multiple delivery systems including, gel, cream, ointment, and spray. This is coupled with the PRP serving as a rich source of exosomes that provide a natural comprehensive means for regeneration. According to Lawrence A Rheins PhD, Chief Scientific Officer, "The additional patent protection offered for SoME® Skincare, will continue to provide Aesthetics Biomedical® with a unique technology platform consisting of stabilized platelet rich plasma, permitting Aesthetics Biomedical® to develop a multitude of topical products for various skin conditions including facial anti-aging."

ABOUT AESTHETICS BIOMEDICAL®: Aesthetics Biomedical® Inc., headquartered in Phoenix, Ariz., is committed to the development and distribution of novel aesthetic devices, products, and services in the global market. Aesthetics Biomedical's innovation center is a leader in breakthrough technologies and combination therapies for its clients, physician network, and the aesthetic arena, creating novel and unique patient experiences that benefit from ongoing research, approved clinical indications for use, as well as a personalized approach designed for consumer benefit. For more information, please visit [AestheticsBiomedical.com.

Media Contact

Jill Eisenstadt Chayet, Aesthetics Biomedical, 1 3106502900, [email protected]

SOURCE Aesthetics Biomedical